1. Home
  2. OVBC vs ICUCW Comparison

OVBC vs ICUCW Comparison

Compare OVBC & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OVBC
  • ICUCW
  • Stock Information
  • Founded
  • OVBC 1872
  • ICUCW N/A
  • Country
  • OVBC United States
  • ICUCW United States
  • Employees
  • OVBC N/A
  • ICUCW 19
  • Industry
  • OVBC Major Banks
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • OVBC Finance
  • ICUCW Health Care
  • Exchange
  • OVBC Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • OVBC N/A
  • ICUCW N/A
  • IPO Year
  • OVBC N/A
  • ICUCW 2021
  • Fundamental
  • Price
  • OVBC $32.14
  • ICUCW $0.03
  • Analyst Decision
  • OVBC
  • ICUCW
  • Analyst Count
  • OVBC 0
  • ICUCW 0
  • Target Price
  • OVBC N/A
  • ICUCW N/A
  • AVG Volume (30 Days)
  • OVBC 8.0K
  • ICUCW N/A
  • Earning Date
  • OVBC 07-25-2025
  • ICUCW N/A
  • Dividend Yield
  • OVBC 2.83%
  • ICUCW N/A
  • EPS Growth
  • OVBC 10.90
  • ICUCW N/A
  • EPS
  • OVBC 2.67
  • ICUCW N/A
  • Revenue
  • OVBC $61,741,000.00
  • ICUCW N/A
  • Revenue This Year
  • OVBC N/A
  • ICUCW N/A
  • Revenue Next Year
  • OVBC N/A
  • ICUCW N/A
  • P/E Ratio
  • OVBC $12.42
  • ICUCW N/A
  • Revenue Growth
  • OVBC 10.84
  • ICUCW N/A
  • 52 Week Low
  • OVBC $19.35
  • ICUCW N/A
  • 52 Week High
  • OVBC $40.99
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • OVBC 38.13
  • ICUCW N/A
  • Support Level
  • OVBC $32.40
  • ICUCW N/A
  • Resistance Level
  • OVBC $33.25
  • ICUCW N/A
  • Average True Range (ATR)
  • OVBC 1.09
  • ICUCW 0.00
  • MACD
  • OVBC -0.65
  • ICUCW 0.00
  • Stochastic Oscillator
  • OVBC 2.02
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: